Thymosin Beta 4 for Enhanced Chemotherapy in Medulloblastoma and Glioblastoma

OVERVIEW

This invention provides a novel method to enhance chemotherapy for treating medulloblastoma and glioblastoma characterized by high basal p53 levels. It involves the use of a PI3K activator, such as thymosin beta 4, in combination with traditional chemotherapy and/or radiation. This innovative approach improves the effectiveness of cancer treatments by targeting cancer cells more precisely while reducing adverse effects on normal cells. For example, thymosin beta 4 can be administered with a chemotherapeutic agent to medulloblastoma patients, leading to increased treatment efficacy and reduced neurocognitive side effects.

BACKGROUND

Medulloblastoma is the most common malignant brain tumor in children, requiring aggressive treatment involving surgery, radiation, and chemotherapy. Glioblastoma is the most prevalent brain cancer in adults, notorious for its poor prognosis despite intensive treatment. Current therapies often result in significant side effects and limited effectiveness, especially for tumors with high p53 levels. This invention addresses these challenges by enhancing the effectiveness of chemotherapy and reducing damage to healthy cells.

Benefit

• Increased Efficacy: Enhances the effectiveness of chemotherapy and radiation, particularly in tumors with high p53 levels.
• Reduced Side Effects: Minimizes adverse effects on normal cells, improving patient quality of life.
• Versatile Application: Suitable for both pediatric medulloblastoma and adult glioblastoma patients.
• Innovative Approach: Introduces a novel use of thymosin beta 4, a PI3K activator, in cancer treatment protocols.
• Improved Survival Rates: Potential to significantly improve survival rates and outcomes in patients with aggressive brain tumors.

Market Application

• Pediatric Oncology: Treatment for childhood medulloblastoma, especially those with high p53 levels.
• Adult Oncology: Therapy for glioblastoma patients, providing a new avenue for those with poor prognosis.
• Neuro-Oncology Centers: Utilization in specialized cancer treatment centers focusing on brain tumors.
• Pharmaceutical Industry: Development of new combination therapies incorporating thymosin beta 4.
• Radiation Oncology: Integrating PI3K activators into radiation therapy protocols to enhance treatment efficacy.

Publications

• Published Patent: US-issued patent No. 11,311,606, detailing the method and application of thymosin beta 4 in enhancing chemotherapy.
• Patent Continuation: CON No. 11,896,650, CONT Filed 18/486,302, providing further insights and developments in the use of PI3K activators.